Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

230
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
230
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

2.2K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.2K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

671
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
671
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

149
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
149
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

151
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
151
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

265
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
265

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiology at the Threshold of a New Biological Era: The Role of Multiomics and Metabolomics.

Kardiologiia·2026
Same author

Impact of Digital Remote Monitoring on the Optimization of Guideline-Directed Medical Therapy Titration in Heart Failure With Reduced Ejection Fraction.

Kardiologiia·2026
Same authorSame journal

Microcirculatory Features of the Conjunctiva and Retina in Patients with Stable Ischemic Heart Disease and Various Patterns of Coronary Artery Involvement.

Kardiologiia·2026
Same author

[Analysis of external respiratory function disturbances in combined pulmonary fibrosis and emphysema].

Terapevticheskii arkhiv·2026
Same author

Integrative Assessment of the Diagnostic Significance of the microRNA (-21, -29a, -133a) Panel in Patients With Hypertrophic Cardiomyopathy in Comparison With the Control Group.

Kardiologiia·2026
Same author

Expert Consensus of the Russian Society of Cardiology, the Society of Heart Failure Specialists, the Russian Association of Oncologists, and the Eurasian Association of Cardio-Oncologists. "Cardioprotection 2025: Modern Approaches to Preventing Cardiovasculatoxicity in Antitumor Therapy". Part II. Primary Prevention of Cardiovasculatoxicity: a Strategy for Protecting the Myocardium and Vessels.

Kardiologiia·2025

Related Experiment Video

Updated: Nov 20, 2025

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.8K

[Circulating Neuregulin-1 and Chronic Heart Failure with Preserved Ejection].

A A Shchendrigina1, K A Zhbanov1, E V Privalova1

  • 1I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow.

Kardiologiia
|January 25, 2021
PubMed
Summary

Chronic heart failure with preserved ejection fraction (CHFpEF) lacks early markers and treatments. Neuregulin-1 (NRG-1) shows promise in improving heart function and reducing inflammation in CHFpEF patients.

More Related Videos

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.1K
Isolation of Endocardial and Coronary Endothelial Cells from the Ventricular Free Wall of the Rat Heart
08:22

Isolation of Endocardial and Coronary Endothelial Cells from the Ventricular Free Wall of the Rat Heart

Published on: April 15, 2020

18.8K

Related Experiment Videos

Last Updated: Nov 20, 2025

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.8K
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.1K
Isolation of Endocardial and Coronary Endothelial Cells from the Ventricular Free Wall of the Rat Heart
08:22

Isolation of Endocardial and Coronary Endothelial Cells from the Ventricular Free Wall of the Rat Heart

Published on: April 15, 2020

18.8K

Area of Science:

  • Cardiology
  • Molecular Biology
  • Pathophysiology

Background:

  • Chronic heart failure with preserved ejection fraction (CHFpEF) presents a significant clinical challenge due to high morbidity and mortality.
  • Current understanding implicates systemic inflammation and endothelial dysfunction in CHFpEF pathogenesis, leading to myocardial fibrosis and diastolic dysfunction.
  • Lack of early diagnostic markers and effective therapies necessitates research into underlying mechanisms and novel therapeutic targets.

Purpose of the Study:

  • To investigate the role of the Neuregulin-1 (NRG-1)/ErbB4 signaling pathway in the early stages of CHFpEF.
  • To evaluate the therapeutic potential of NRG-1 in improving cardiac function and remodeling in CHFpEF.
  • To explore the anti-inflammatory and antifibrotic effects of NRG-1 in the context of CHFpEF.

Main Methods:

  • Review of current literature on CHFpEF pathogenesis and the NRG-1/ErbB4 system.
  • Analysis of preclinical and clinical (phases II and III) data regarding recombinant NRG-1 therapy.
  • Examination of emerging evidence on the molecular effects of NRG-1, including anti-inflammatory and antifibrotic actions.

Main Results:

  • The NRG-1/ErbB4 system is activated early in CHFpEF, enhancing cardiomyocyte resistance to oxidative stress.
  • Recombinant NRG-1 therapy has demonstrated improvements in myocardial contractility and left ventricular (LV) reverse remodeling in preclinical and clinical studies.
  • Recent findings suggest NRG-1 possesses anti-inflammatory and antifibrotic properties relevant to CHFpEF.

Conclusions:

  • The NRG-1/ErbB4 pathway is a key player in the early stages of CHFpEF and warrants further investigation.
  • NRG-1 therapy holds potential for improving cardiac function and remodeling in CHFpEF patients.
  • Targeting the NRG-1 system may offer a novel therapeutic strategy for CHFpEF, addressing its inflammatory and fibrotic components.